Keymed Biosciences Announces 2023 Annual Results and Business Updates ...Middle East

Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA and granted priority review. Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of...

Hence then, the article about keymed biosciences announces 2023 annual results and business updates was published today ( Tuesday 26/03/2024 - 08:17 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences Announces 2023 Annual Results and Business Updates )

Also on site :

• ‘Change is inevitable’: What is next for Iran?
• Australian Open: Sinner overcomes cramps; Keys, Pegula advance; Osaka withdraws
• Most People Watching XRP Through Wrong Lens As XRP Underperforms: Black Swan Capitalist founder